Fig. 1From: Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistancePrimary endpoint analyses. Primary endpoint (PE) analyses in the exposed intention-to-treat (ITTe) analysis population, overall and in the subgroups based on treatment experience and history/presence of resistance-associated mutation (RAMs). RT resistance testing, NRTI nucleoside/nucleotide reverse transcriptase inhibitor, PI protease inhibitorBack to article page